Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
The Inflation Reduction Act's negotiation period for Medicare drug prices has concluded, paving the way for potentially more affordable drugs by 2026. A recent analysis by KFF highlights that changes stemming from this act may influence Medicare Part D premiums for 2025, though actual premium figures will not be available until September. The Centers for Medicare & Medicaid Services (CMS) is implementing measures to address potential premium increases through a new demonstration program for stand-alone drug plans and payment adjustments aimed at stabilizing the market. Initial data from bids by Part D plans for 2025 indicates that costs have risen significantly due to the Inflation Reduction Act.
Earlier this week CMS released initial data from bids by Part D (prescription drug insurance for seniors) plans to provide coverage in 2025. As anticipated, the Inflation Reduction Act, has driven costs higher...significantly higher. 🧵 https://t.co/huz3U9j5Qr
The Centers for Medicare & Medicaid Services is taking steps to mitigate potential Part D premium increases through a new demonstration program for stand-alone drug plans, and payment changes designed to bring more stability to the market in 2025. 👇 https://t.co/1TgIM3TD0d
Medicare Part D is mind numbingly complex. We explain how it works, and how and why premiums might be changing next year as the benefit improves with lower out-of-pocket costs. https://t.co/gqCzm0YXpE
